STOCK TITAN

Idexx Laboratories Inc - IDXX STOCK NEWS

Welcome to our dedicated page for Idexx Laboratories news (Ticker: IDXX), a resource for investors and traders seeking the latest updates and insights on Idexx Laboratories stock.

IDEXX Laboratories, Inc. (NASDAQ: IDXX) is a global leader in pet healthcare innovation, providing a broad range of diagnostic and information technology-based products and services to practicing veterinarians across the globe. Headquartered in Southern Maine, the company operates through more than 70 locations worldwide, serving customers in over 175 countries and employing more than 11,000 people.

IDEXX’s primary business focuses on pet health, offering products such as in-clinic diagnostic tests, instrumentation, reference laboratory and telemedicine consultation services, and practice management software. These products enhance veterinarians' ability to provide advanced medical care, improve staff efficiency, and build more economically successful practices. The company is also involved in developing diagnostic tests for the global production animal industry, including poultry and livestock, and tests for the quality and safety of water.

An important recent achievement for IDEXX is the launch of the SNAP® Leish 4Dx® Test, designed to diagnose vector-borne diseases like canine leishmaniosis in regions where these diseases are endemic. This new test will be available in Europe and Asia starting February 2024. Another significant accomplishment is the expansion of the Fecal Dx® antigen testing platform, which includes the addition of Cystoisospora, a common intestinal parasite. This expansion will roll out in North America in March 2024 and globally by the third quarter of 2024.

IDEXX also launched Vello, a software solution aimed at improving communication between veterinary practices and pet owners. This tool supports better health outcomes by engaging pet owners through digital means and is integrated with IDEXX's existing practice management software like ezyVet®, Neo®, and Cornerstone®.

Financially, IDEXX is robust, with a diverse revenue stream sourced from various products and services, including diagnostic equipment, tests, and software solutions. Approximately 35% of its revenue comes from international markets. The company is a member of the S&P 500® Index, highlighting its significant role in the industry.

For more information about IDEXX’s products and services, visit idexx.com.

Rhea-AI Summary
IDEXX Laboratories, Inc. (NASDAQ: IDXX) will participate in two upcoming institutional investor events. Jay Mazelsky, President and CEO, will join the Goldman Sachs Healthcare C-Suite Unscripted Conference in New York, New York on January 4, 2024, and will host an Investor and Analyst Session at VMX in Orlando, Florida on January 15, 2024, to highlight IDEXX’s new point of care analyzer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.58%
Tags
none
-
Rhea-AI Summary
IDEXX Laboratories, Inc. (NASDAQ: IDXX) announced the upcoming launch of the SNAP® Leish 4Dx® Test, a comprehensive screening test for vector-borne diseases, including canine leishmaniosis. The test uses the trusted SNAP 4Dx Plus testing platform and will be available in Europe and Asia beginning February 2024. The launch provides veterinarians with an end-to-end solution for vector-borne disease testing, including streamlined reference laboratory follow-up testing and compatibility with the SNAP Pro® Analyzer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
none
-
Rhea-AI Summary
IDEXX Laboratories, Inc. reports third quarter revenue growth of 9% reported and 8% organic. EPS increases by 18% as reported and 16% on a comparable basis. Adjusts 2023 revenue guidance to $3,635 million - $3,650 million. Updates 2023 EPS outlook to $9.74 - $9.90.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
Rhea-AI Summary
IDEXX Laboratories to release 2023 Q3 results on November 1, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.59%
Tags
-
Rhea-AI Summary
IDEXX Laboratories, Inc. (NASDAQ: IDXX) reports 10% revenue growth in the second quarter of 2023, driven by CAG Diagnostics recurring revenue growth of 11%. The company achieved record global premium instrument placements and delivered EPS of $2.67, representing 71% growth. Updates 2023 revenue guidance to $3,660 million - $3,715 million and increases 2023 EPS outlook to $9.64 - $9.90.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.04%
Tags
-
Rhea-AI Summary
IDEXX Laboratories, Inc. (NASDAQ: IDXX) published its 2022 Corporate Responsibility Report, highlighting progress against ESG goals and introducing a new framework aligning ESG initiatives with long-term strategy. The report focuses on environmental and social priorities, including expanded product enhancements, support for veterinary mental health, gender balance in management roles, career progression programs, pay equity assessment, GHG emissions reduction strategy, and transition to environmentally friendly packaging and vehicles.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
none
Rhea-AI Summary
IDEXX Laboratories, Inc. (NASDAQ: IDXX) announced the election of Irene Chang Britt, a former executive at Campbell Soup Company, to the Company's Board of Directors. The addition of Ms. Chang Britt brings valuable business and strategic experience to the board, enhancing the company's focus on pet healthcare innovation and long-term stakeholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.11%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.09%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.2%
Tags
conferences

FAQ

What is the current stock price of Idexx Laboratories (IDXX)?

The current stock price of Idexx Laboratories (IDXX) is $417.11 as of December 26, 2024.

What is the market cap of Idexx Laboratories (IDXX)?

The market cap of Idexx Laboratories (IDXX) is approximately 33.9B.

What is IDEXX Laboratories, Inc.?

IDEXX Laboratories, Inc. (NASDAQ: IDXX) is a global leader in pet healthcare innovation, providing a wide range of diagnostic and information technology-based products and services to veterinarians worldwide.

Where is IDEXX Laboratories headquartered?

IDEXX Laboratories is headquartered in Southern Maine, USA.

What are some key products and services offered by IDEXX?

IDEXX offers in-clinic diagnostic tests, reference laboratory and telemedicine consultation services, practice management software, diagnostic tests for production animals, and tests for water safety.

What recent products has IDEXX Laboratories launched?

IDEXX has recently launched the SNAP® Leish 4Dx® Test for vector-borne diseases and expanded its Fecal Dx® antigen testing platform to include Cystoisospora.

How many countries does IDEXX Laboratories serve?

IDEXX Laboratories serves customers in over 175 countries.

How many people does IDEXX Laboratories employ?

IDEXX Laboratories employs more than 11,000 people globally.

What is the new software solution IDEXX launched?

IDEXX launched Vello, a software solution that connects veterinary practices with pet owners through modern digital tools, integrated with existing practice management software.

What percentage of IDEXX's revenue comes from international markets?

Approximately 35% of IDEXX’s revenue comes from international markets.

Is IDEXX part of any major stock index?

Yes, IDEXX Laboratories is a member of the S&P 500® Index.

Where can I find more information about IDEXX's products and services?

For more information, you can visit IDEXX's official website at idexx.com.

Idexx Laboratories Inc

Nasdaq:IDXX

IDXX Rankings

IDXX Stock Data

33.91B
81.34M
0.94%
94.34%
1.98%
Diagnostics & Research
In Vitro & in Vivo Diagnostic Substances
Link
United States of America
WESTBROOK